临床路径在ABO溶血病诊疗中的卫生经济学评价  

Health Economic Evaluation of the Clinical Path in the Diagnosis and Treatment of ABO Hemolytic disease

作　　者：魏琛[1] 董慧芳[1] 王芳[1] 

机构地区：[1]郑州大学第三附属医院,河南郑州450052

出　　处：《中国医药指南》2013年第10期22-23,共2页Guide of China Medicine

摘　　要：目的对实施临床路径前后ABO血型不合溶血病的诊疗程序进行卫生经济学评价。方法对2008年6月至2009年5月及2010年1月至2010年12月我院新生儿科确诊的ABO血型不合溶血病患儿进行回顾性分析,分为路径组和对照组,分别就其住院时间、总费用、药费、药品比等卫生经济学指标进行分析。比较临床路径实施前后单病种住院患者的医疗费用构成及费用差异。结果较之临床路径实施前,实行临床路径后医疗费用和药费没有显著性差异(P>0.05),治疗费有显著性减少(P<0.05)。住院天数是影响医疗费用变化的主要因素。结论设计合理的临床路径能够控制医疗费用的增长,缩短住院天数和控制药费是临床路径合理化的关键因素。Objeetive Using the health economies analysis in newborn hemolytic disease expenditure between before and after Clinical Pathway（CP）. Method Compare the component and difference of the newborn hemolytic disease expenditure between before and after CP, analyze the key taches of CP. Results The expenditure diversity and the druggery fees of newbom hemolytic disease between before and after CP shows no statistical significance（P〉0.05）, the treatment fees decrease after CP（P〈0.05）. The hospital days are the primary factor to expenditure of newborn hemolytie disease. Conclusions The reasonably designed CP is an effective approach to control medical expenditure,the key factor to make CP reasonably is to shorten the hospital days and control druggery fees.

关 键 词：临床路径 新生儿溶血病 卫生经济学 费用控制 

分 类 号：R722.1[医药卫生—儿科]